Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Prime Medicine (PRME) Return on Invested Capital (2022 - 2024)

Historic Return on Invested Capital for Prime Medicine (PRME) over the last 4 years, with Q1 2025 value amounting to 1.59%.

  • Prime Medicine's Return on Invested Capital fell 4600.0% to 1.59% in Q1 2025 from the same period last year, while for Mar 2025 it was 1.59%, marking a year-over-year decrease of 4600.0%. This contributed to the annual value of 0.91% for FY2023, which is 5400.0% up from last year.
  • Per Prime Medicine's latest filing, its Return on Invested Capital stood at 1.59% for Q1 2025, which was down 4600.0% from 1.01% recorded in Q2 2024.
  • Prime Medicine's 5-year Return on Invested Capital high stood at 0.66% for Q3 2022, and its period low was 2.48% during Q4 2022.
  • Over the past 4 years, Prime Medicine's median Return on Invested Capital value was 0.91% (recorded in 2024), while the average stood at 0.8%.
  • Within the past 5 years, the most significant YoY rise in Prime Medicine's Return on Invested Capital was 12300bps (2023), while the steepest drop was -14700bps (2023).
  • Over the past 4 years, Prime Medicine's Return on Invested Capital (Quarter) stood at 2.48% in 2022, then skyrocketed by 50bps to 1.25% in 2023, then rose by 19bps to 1.01% in 2024, then plummeted by -56bps to 1.59% in 2025.
  • Its Return on Invested Capital stands at 1.59% for Q1 2025, versus 1.01% for Q2 2024 and 1.13% for Q1 2024.